KB02-JQ1 is primarily utilized in the field of cancer research, particularly in the study of epigenetics and gene regulation. It functions as a potent and selective inhibitor of BET (bromodomain and extra-terminal) proteins, which play a critical role in controlling the expression of genes involved in cell growth and proliferation. By inhibiting these proteins, KB02-JQ1 helps researchers investigate the mechanisms behind cancer development and progression, offering insights into potential therapeutic strategies. Additionally, it is used in preclinical studies to evaluate its efficacy in targeting various cancers, including leukemia, lymphoma, and solid tumors. Its application extends to understanding the role of BET proteins in inflammatory diseases and other conditions driven by abnormal gene expression.